Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Med III Drugs
Med Knowledge III All Drugs
| Term | Definition |
|---|---|
| brand name of amoxicillin | amoxil |
| brand name of amoxicillin/clavulanic acid | augmentin |
| brand name of penicillin g | n/a |
| brand name of penicillin vk | pen-vk |
| brand name of piperacillin/tazobactam | zosyn |
| brand name of cephalexin | keflex |
| brand name of cefazolin | ancef (iv) |
| brand name of cefuroxime | ceftin |
| brand name of ceftriaxone | rocephin (iv/im) |
| brand name of cefdinir | omnicef |
| brand name of cefepime | maxipime (iv) |
| brand name of ertapenem | invanz (iv) |
| brand name of meropenem | merrem (iv) |
| therapeutic class of amoxicillin | antibacterial |
| therapeutic class of amoxicillin/clavulanic acid | antibacterial |
| therapeutic class of penicillin g | antibacterial |
| therapeutic class of penicillin vk | antibacterial |
| therapeutic class of cephalexin | antibacterial |
| therapeutic class of cefazolin | antibacterial |
| therapeutic class of cefuroxime | antibacterial |
| therapeutic class of ceftriaxone | antibacterial |
| therapeutic class of cefdinir | antibacterial |
| therapeutic class of cefepime | antibacterial |
| therapeutic class of ertapenem | antibacterial |
| therapeutic class of meropenem | antibacterial |
| therapeutic class of piperacillin/tazobactam | antibacterial |
| pharmacologic class of amoxicillin | aminopenicillin |
| pharmacologic class of amoxicillin/clavulanic acid | aminopenicllin + beta lactamase inhibitor |
| pharmacologic class of penicillin g | natural penicillin |
| pharmacologic class of penicillin vk | natural penicillin |
| pharmacologic class of piperacillin/tazobactam | extended spectrum penicillin + beta lactamase inhibitor |
| pharmacologic class of cephalexin | 1st gen cephalosporin |
| pharmacologic class of cefazolin | 1st gen cephalosporin |
| pharmacologic class of cefuroxime | 2nd gen cephalosporin |
| pharmacologic class of ceftriaxone | 3rd gen cephalosporin |
| pharmacologic class of cefdinir | 3rd gen cephalosporin |
| pharmacologic class of cefepime | 4th gen cephalosporin |
| pharmacologic class of ertapenem | carbapenem |
| pharmacologic class of meropenem | carbapenem |
| major characteristic of amoxicillin | GI upset or rash |
| major characteristic of amoxicillin/clavulanic acid | GI upset or rash |
| major characteristic of penicillin g | GI upset or rash |
| major characteristic of penicillin vk | GI upset or rash |
| major characteristic of piperacillin/tazobactam | GI upset or rash |
| major characteristic of cephalexin | GI upset or rash |
| major characteristic of cefazolin | GI upset or rash |
| major characteristic of cefuroxime | GI upset or rash |
| major characteristic of ceftriaxone | GI upset or rash |
| major characteristic of cefdinir | GI upset or rash |
| major characteristic of cefepime | GI upset or rash |
| major characteristic of ertapenem | GI upset or rash |
| major characteristic of meropenem | GI upset or rash |
| MOA of amoxicillin | binds to penicillin binding protein inhibiting cell wall synthesis |
| MOA of amoxicillin/clavulanic acid | binds to penicillin binding protein to inhibit cell wall synthesis and inhibits beta-lactamase enzyme |
| MOA of penicillin g | binds to penicillin binding protein to inhibit cell wall synthesis |
| MOA of penicillin vk | binds to penicillin binding protein to inhibit cell wall synthesis |
| MOA of piperacillin/tazobactam | binds to penicillin binding protein to inhibit cell wall synthesis and inhibits beta-lactamase enzyme |
| MOA of cephalexin | binds to penicillin binding protein to inhibit cell wall synthesis |
| MOA of cefazolin | binds to penicillin binding protein to inhibit cell wall synthesis |
| MOA of cefuroxime | binds to penicillin binding protein to inhibit cell wall synthesis |
| MOA of ceftriaxone | binds to penicillin binding protein to inhibit cell wall synthesis |
| MOA of cefdinir | binds to penicillin binding protein to inhibit cell wall synthesis |
| MOA of cefepime | binds to penicillin binding protein to inhibit cell wall synthesis |
| MOA of ertapenem | binds to penicillin binding protein to inhibit cell wall synthesis |
| MOA of meropenem | binds to penicillin binding protein to inhibit cell wall synthesis |
| brand name of azithromycin | zithromax |
| brand name of erythromycin | EES |
| brand name of clarithromycin | biaxin |
| brand name of gatifloxacin | zymar (optic) |
| brand name of levofloxacin | levaquin |
| brand name of ciprofloxacin | cipro |
| brand name of moxifloxacin | avelox |
| brand name of doxycycline | vibramycin |
| brand name of minocycline | minocin |
| brand name of sulfamethoxazole/trimethoprim (smx/tmp) | bactrim;septra |
| brand name of clindamycin | cleocin |
| brand name of nitrofurantoin | macrobid |
| brand name of metronidazole | flagyl |
| therapeutic class of azithromycin | antibacterial |
| therapeutic class of erythromycin | antibacterial |
| therapeutic class of clarithromycin | antibacterial |
| therapeutic class of gatifloxacin | antibacterial |
| therapeutic class of levofloxacin | antibacterial |
| therapeutic class of ciprofloxacin | antibacterial |
| therapeutic class of moxifloxacin | antibacterial |
| therapeutic class of doxycycline | antibacterial |
| therapeutic class of minocycline | antibacterial |
| therapeutic class of sulfamethoxazole/trimethoprim | antibacterial |
| therapeutic class of clindamycin | antibacterial |
| therapeutic class of nitrofurantoin | antibacterial |
| therapeutic class of metronidazole | antibacterial |
| pharmacologic class of azithromycin | macrolide |
| pharmacologic class of erythromycin | macrolide |
| pharmacologic class of clarithromycin | macrolide |
| pharmacologic class of gatifloxacin | quinolone |
| pharmacologic class of levofloxacin | quinolone |
| pharmacologic class of ciprofloxacin | quinolone |
| pharmacologic class of moxifloxacin | quinolone |
| pharmacologic class of doxycycline | tetracycline |
| pharmacologic class of minocycline | tetracycline |
| pharmacologic class of sulfamethoxazole/trimethoprim | sulfonamide + dihydrofolate reductase inhibitor |
| pharmacologic class of clindamycin | lincosamide |
| pharmacologic class of nitrofurantoin | nitrofuran |
| pharmacologic class of metronidazole | nitroimidazole |
| major characteristic of azithromycin | risk of QTc prolongation |
| major characteristic of erythromycin | risk of QTc prolongation |
| major characteristic of clarithromycin | risk of QTc prolongation |
| major characteristic of gatifloxacin | avoid taking with calcium products |
| major characteristic of levofloxacin | avoid taking with calcium products |
| major characteristic of ciprofloxacin | avoid taking with calcium products |
| major characteristic of moxifloxacin | avoid taking with calcium products |
| major characteristic of doxycycline | photosensitivity |
| major characteristic of minocycline | photosensitivity |
| major characteristic of sulfamethoxazole/trimethoprim | photosensitivity and rash |
| major characteristic of clindamycin | GI adverse effects |
| major characteristic of nitrofurantoin | concentrates in the bladder |
| major characteristic of metronidazole | GI upset and metallic taste |
| MOA of azithromycin | binds to the 50S subunit of bacterial ribosomes |
| MOA of erythromycin | binds to the 50S subunit of bacterial ribosomes |
| MOA of clarithromycin | binds to the 50S subunit of bacterial ribosomes |
| MOA of gatifloxacin | prevents untangling of double stranded DNA breakage leading to cell death |
| MOA of levofloxacin | prevents untangling of double stranded DNA breakage leading to cell death |
| MOA of moxifloxacin | prevents untangling of double stranded DNA breakage leading to cell death |
| MOA of ciprofloxacin | prevents untangling of double stranded DNA breakage leading to cell death |
| MOA of doxycycline | binds to the 30S subunit to prevent protein synthesis |
| MOA of minocycline | binds to the 30S subunit to prevent protein synthesis |
| MOA of SMX/TMP | stops bacterial growth by blocking sequential steps in folic acid synthesis |
| MOA of clindamycin | binds to 50S subunit of ribosome to prevent RNA synthesis |
| MOA of nitrofurantoin | disrupts protein synthesis by forming toxic metabolites |
| MOA of metronidazole | disrupts protein synthesis by forming toxic metabolites |
| brand name of albendazole | albenza |
| brand name of clotrimazole/betamethasone | lotrisone |
| brand name of fluconazole | diflucan |
| brand name of ketoconazole | nizoral |
| brand name of miconazole | monistat/lotrimin |
| brand name of nystatin | N/A |
| therapeutic class of albendazole | antiparasitic |
| therapeutic class of clotrimazole/bethamethasone | antifungal |
| therapeutic class of fluconazole | antifungal |
| therapeutic class of ketoconazole | antifungal |
| therapeutic class of miconazole | antifungal |
| therapeutic class of nystatin | antifungal |
| pharmacologic class of albendazole | benzimidazole |
| pharmacologic class of clotrimazole/bethamethasone | imidazole |
| pharmacologic class of fluconazole | triazole |
| pharmacologic class of ketoconazole | imidazole |
| pharmacologic class of miconazole | imidazole |
| pharmacologic class of nystatin | polyene |
| MOA of albendazole | inhibits microtubule synthesis in parasites which prevents formation of cell structure and uptake of glucose |
| MOA of clotrimazole/betamethasone | prevents the formation of ergosterol which is the building block of fungal cell membrane |
| MOA of fluconazole | prevents the formation of ergosterol which is the building block of fungal cell membrane |
| MOA of ketoconazole | prevents the formation of ergosterol which is the building block of fungal cell membrane |
| MOA of miconazole | prevents the formation of ergosterol which is the building block of fungal cell membrane |
| MOA of nystatin | binds to ergosterol to create pores in the fungal cell membrane causing cell death |
| major characteristic of albendazole | needs high fat meal for absorption |
| major characteristic of clotrimazole/betamethasone | drug-drug interactions (CYP450's) |
| major characteristic of fluconazole | drug-drug interactions (CYP450's) |
| major characteristic of ketoconazole | drug-drug interactions (CYP450's) |
| major characteristic of miconazole | drug-drug interactions (CYP450's) |
| major characteristic of nystatin | localized skin irritation |
| brand name of acyclovir | zovirax |
| brand name of valacyclovir | valtrex |
| brand name of oseltamivir | tamiflu |
| brand name of baloxavir | xofluza |
| therapeutic class of acyclovir | antiviral |
| therapeutic class of valacyclovir | antiviral |
| therapeutic class of oseltamivir | antiviral |
| therapeutic class of baloxavir | antiviral |
| pharmacologic class of acyclovir | nucleoside analog |
| pharmacologic class of valacyclovir | nucleoside analog |
| pharmacologic class of oseltamivir | neuraminidase inhibitor |
| pharmacologic class of baloxavir | endonuclease inhibitor |
| major characteristic of acyclovir | GI side effects |
| major characteristic of valacyclovir | GI side effects |
| major characteristic of oseltamivir | GI upset |
| major characteristic of baloxavir | GI upset |
| MOA of acyclovir | inhibits DNA polymerase and incorporates into DNA to stop transcription |
| MOA of valacyclovir | inhibits DNA polymerase and incorporates into DNA to stop transcription |
| MOA of oseltamivir | prevents viral particles from being released from infected cells |
| MOA of baloxavir | disrupts RNA synthesis to prevent viral replication |
Created by:
lainey2790
Popular Pharmacology sets